Teva Pharma (TEVA) to Acquire Auspex Pharma (ASPX) in $3.2B Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Teva Pharma (TEVA) 'Transformational' Deal Still Possible Following Auspex, Jefferies Says
March 31, 2015 8:27 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and $66 price target on Teva Pharma (NYSE: TEVA) after the company entered into a definitive agreement to acquire Auspex (ASPX) for $3.2B. The analyst continues to believe that a large "transformational" acquisition is still a... More
William Blair Downgrades Auspex Pharmaceuticals (ASPX) to Market Perform
March 31, 2015 7:09 AM EDTWilliam Blair downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $100.36 yesterday.
... MoreStifel Downgrades Auspex Pharmaceuticals (ASPX) to Hold
March 31, 2015 7:07 AM EDTStifel downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Buy to Hold.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $100.36 yesterday.
... MoreBaird Downgrades Auspex Pharmaceuticals (ASPX) to Neutral
March 31, 2015 7:06 AM EDTBaird downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Outperform to Neutral.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $100.36 yesterday.
... MoreOppenheimer Upgrades Teva Pharma (TEVA) to Outperform
March 31, 2015 6:48 AM EDTOppenheimer upgraded Teva Pharma (NYSE: TEVA) from Perform to Outperform with a price target of $77.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $62.52 yesterday.
... MoreTeva Pharma (TEVA) Price Target Raised to $68 at Deutsche Bank; Large & Small Deals Remain Priority, Notes Analyst
March 30, 2015 1:59 PM EDTDeutsche Bank maintained a Buy rating on Teva Pharma (NYSE: TEVA) and raised is price target to $68.00 (from $67.00). Earlier Teva announced a deal to acquire Auspex Pharmaceuticals (NASDAQ: ASPX). Analyst Gregg Gilbert pointed out that this... More
BMO Capital Downgrades Auspex Pharmaceuticals (ASPX) to Market Perform on Takeover
March 30, 2015 11:57 AM EDTBMO Capital downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Outperform to Market Perform after the company agreed to be acquired by Teva Pharmaceuticals this morning.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals... More
Piper Jaffray Downgrades Auspex Pharmaceuticals (ASPX) to Neutral
March 30, 2015 11:08 AM EDTPiper Jaffray downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $70.91 yesterday.
... MoreTeva (TEVA) Gains as Bernstein Discusses 'Transformational Deal'; Lifts PT to $69
March 26, 2015 10:46 AM EDTTeva Pharma (NYSE: TEVA) is gaining early (+2%) Thursday following bullish comments from Bernstein analyst Ronny Gal. The analyst reiterated an Outperform rating while raising his price target to $69.00 (from $60.00), noting business progress even as the company struggles with the ''transformational deal." Gal's comments follows participation in a series of investor meetings with Teva executives in Israel.
On business development, the analyst notes, "The Teva message on business development was a similar, if richer, version of the one previously given. Teva's strategy is to gradually shift the... More
